Investors & Media

Event Details

Investors & Media

Event Details

2022 Society for Neuro-Oncology (SNO) Annual Meeting

Nov 18, 2022

Supporting Materials

FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors 953.4 KB

LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric patients with newly diagnosed low-grade glioma harboring an activating RAF alteration 481.7 KB

Investor Contact

Investor Relations
investors@dayonebio.com

Media Contact

Laura Cooper
Media@dayonebio.com

Helpful Tools